Welcome to our dedicated page for Preveceutical news (Ticker: PRVCF), a resource for investors and traders seeking the latest updates and insights on Preveceutical stock.
PreveCeutical Medical Inc. (PRVCF) is an innovative health sciences company developing preventive and curative therapies through advanced biotechnology research. This page serves as the definitive source for verified news and official updates about the company's scientific advancements and corporate developments.
Investors and researchers will find timely updates on PRVCF's progress across multiple therapeutic programs, including its nature-identical peptide research, Sol-Gel drug delivery platform, and non-addictive pain management solutions. Our curated news feed ensures stakeholders stay informed about material events including clinical trial milestones, intellectual property filings, and strategic partnership announcements.
The news collection focuses on three key areas: Research Breakthroughs (gene therapy progress, preclinical study results), Operational Updates (regulatory filings, financial disclosures), and Strategic Developments (collaborations, patent grants). Each update is verified against original source materials to ensure accuracy.
Bookmark this page for streamlined access to PRVCF's latest advancements in preventive health sciences. For comprehensive analysis of how these developments may impact long-term research trajectories, consider subscribing to our investment research updates.
PreveCeutical Medical Inc. (PRVCF) has announced a new program to develop their Nose to Brain (N2B) Sol-Gel platform for delivering Dopamine and L-Dopa directly to the brain for Parkinson's disease treatment. The technology is designed to bypass the Blood Brain Barrier (BBB), which could potentially improve drug bioavailability while reducing side effects associated with current delivery methods.
The company expects this approach to enhance safety and effectiveness by avoiding systemic exposure and requiring lower therapeutic doses through direct brain targeting. The N2B platform's ability to bypass other body compartments could lead to reduced drug dosages and improved patient compliance.
PreveCeutical plans to demonstrate proof of concept in preclinical models before seeking partnerships with organizations specializing in Parkinson's disease.
PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) has appointed Dr. Bryan Jones as Director of Sol-Gel Special Projects, effective January 31, 2025. Dr. Jones brings over 30 years of drug development experience and currently serves as Chief Operating Officer of Aardvark Therapeutics. His extensive background includes co-founding Sollis Therapeutics and Sherrington Pharmaceuticals, with experience at Bristol-Myers Squibb and work on products like Cialis.
Dr. Jones holds a Ph.D. in Genetics from the University of Washington and will focus on advancing PreveCeutical's Sol-Gel program for Nose to Brain delivery of therapeutics. The company aims to develop preventive and curative therapies using organic and nature identical products. CEO Stephen Van Deventer expressed that Dr. Jones's expertise will help accelerate the program, with details on their first targeted therapeutic forthcoming.
PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) has announced that its subsidiary BioGene Therapeutics will participate in the 43rd JP Morgan Healthcare Conference from January 13-16, 2025, in San Francisco.
The company's leadership team attending includes Dr. Harry Parekh (Chief Research Officer & Scientific Founder), along with board members Dr. Deepak Sampath, Steve Glover, and Patroski J. Lawson. BioGene, under parent company PreveCeutical, focuses on developing innovative preventive and curative therapies using organic and nature-identical products.
CEO Stephen Van Deventer emphasized the importance of having their Scientific Founder and experienced team members present to showcase their accomplishments and future plans. Interested parties can request meetings with the team via info@biogenetherapeutics.com.
PreveCeutical Medical (CSE: PREV) (OTCQB: PRVCF) has announced a change in its auditing firm. The company's board of directors has accepted the resignation of Smythe LLP as their former auditor and appointed Davidson & Company LLP as the successor auditor, effective December 18, 2024. The new auditor will serve until the company's next annual general meeting of shareholders.
The company confirms there were no reservations in the former auditor's reports during their tenure, and no reportable events exist between PreveCeutical and Smythe LLP. The required documentation, including the Notice of Change of Auditor and letters from both auditing firms, has been reviewed by the audit committee and board of directors and will be filed on SEDAR.
PreveCeutical Medical announced that its subsidiary BioGene Therapeutics has appointed Patroski J. Lawson as an independent director effective December 6, 2024. According to CEO Stephen Van Deventer, Lawson brings extensive experience in government affairs across local, state, federal, and global levels, particularly within the healthcare sector. The company expects his strategic insights and leadership to strengthen their governance and advocacy efforts as they navigate the regulatory landscape in developing innovative therapies.
PreveCeutical Medical's subsidiary BioGene Therapeutics has appointed Dr. Barry Ticho to its Scientific Advisory Board effective December 1, 2024. Dr. Ticho brings over 25 years of biopharma and drug development expertise, currently serving as Chief Medical Officer at Stoke Therapeutics. His experience includes co-founding Verve Therapeutics and leading R&D initiatives at Moderna Therapeutics, Pfizer, and Biogen.
Dr. Ticho has notably transformed Stoke from a 9-employee private company to a publicly traded organization with over 100 employees, focusing on genetic diseases in neurology and ophthalmology. He holds an MD and PhD from the University of Chicago and serves on multiple Scientific Advisory Boards including Cardior Pharmaceuticals, Mana.bio, and Sania.
PreveCeutical Medical's subsidiary BioGene Therapeutics has appointed Dr. Brian Gallagher, Jr. to its Corporate Advisory Board effective December 1, 2024. Dr. Gallagher brings over 25 years of experience in biotech and pharmaceutical investments, having served as Managing Partner at Trekk Venture Partners and Partner at Abingworth. His notable achievements include overseeing Sirtris Pharmaceuticals' $720 million acquisition by GlaxoSmithKline and contributing to Translate Bio's $3.2 billion acquisition by Sanofi.
Dr. Gallagher holds a Ph.D. in Organic Chemistry from the University of Michigan and has served as Chairman of eFFECTOR Therapeutics. His expertise spans venture capital, strategic investments, and corporate development within the biotech sector.
PreveCeutical Medical announced that its subsidiary BioGene Therapeutics has appointed Stephen Glover as an independent director effective November 30, 2024. The company's CEO, Stephen Van Deventer, highlighted Glover's expertise in biopharma, corporate strategy, commercialization, and financial management, noting his track record in building and transforming organizations aligns with BioGene's mission to advance groundbreaking therapies.
PreveCeutical Medical's subsidiary BioGene Therapeutics has appointed Dr. Deepak Sampath as an independent director effective November 21, 2024. Dr. Sampath brings over 25 years of experience in molecular biology, pharmacology, and drug development. Currently serving as Senior Vice President and Head of Research at Ultragenyx, he has contributed significantly to oncological treatments, including the FDA approval of venetoclax for CLL/SLL. His expertise spans protein biologics, nucleic acids, and gene therapies, with 108 published articles and involvement in 32 patents/applications. At Ultragenyx, he leads research in genetic conditions across neurological, metabolic, bone, and muscular diseases.
PreveCeutical Medical announced that its subsidiary BioGene Therapeutics has appointed Professor Mirela Delibegovic, FRSE to its Scientific Advisory Board effective November 19, 2024. The company, which focuses on developing preventive and curative therapies using organic and nature-identical products, expects to benefit from Delibegovic's expertise in obesity and diabetes physiology and signaling research to advance their therapeutic programs in metabolic health.
FAQ
What is the current stock price of Preveceutical (PRVCF)?
What is the market cap of Preveceutical (PRVCF)?
